Junior  Research Groups:  GPCR 1   

Junior
Research Groups:
GPCR 1

Junior Research Group GPCR 1 ligand binding

The training research group headed by Dr. Sylvia Els-Heindl be promoted by the Saxon State Ministry for Science and Art from July 2013 to Dezember 2014.

7 young scientists graduating in research projects for the development of novel drugs for treatment of serious diseases. The focus of the training research group is biosynthesis, binding and signal transduction molecules to their receptors. Hormones and transmitters have a regulatory effect in a particular way to the cellular material budget and can cause to malfunctions and common diseases, such as hypertension, obesity, neuronal malfunction or pain. To meet this challenge in the future the research and technology knowhow located in Saxony has to be development. The core point is planned to deal with the exploration of novel drugs and performance tests.

The training research group is led by internationally renowned scientists at the Leipzig University and are implemented in close collaboration with the involved scientists from Vanderbilt University.

Research

G protein-coupled receptors (GPCRs) have comprehensive and fundamental tasks in the signal transduction and the regulation of cellular metabolic budget, and my give rise malfunction to serious diseases such as hypertension, obesity, neuronal malfunction or pain. Rationally designed novel ligands are potentially high-affinity novel drugs. Notwithstanding the previously successfully developed drugs against GPCRs, shown still fundamental difficulties in the development of appropriate test methods (assays) for the development process of drugs (drug discovery).

In the training research group " GPCR 1 ligand binding " the focus is on the development and influence of the ligands and their structural elucidation. Many GPCRs are experimentally not accessible or only with considerable effort. In any other class of target proteins for drug development, the quality of the validated targets and the experimental accessibility of the proteins are in such a blatant mismatch. There are numerous applications for use in the modulation of the function of GPCRs. Here inhibitors or agonists play an important role. Novel receptors in pain are modulators of neuropeptide FF multi-ligand / multi-receptor system. In the development of novel ligands in the field of NPY and Ghrelin receptors, this interesting potential targets play a major role in the field of food regulation and intake. The focus of the sub-projects is on the biosynthesis and attachment of to GPCRs, and in particular the development of new ligands. Because of the immense difficulties in the development of appropriate test method for the drugs development, various receptor models and structures will be studied and characterized. Another objective is the development of novel ligands as potential pharmaceutical agents which have an influence on the GPCR system.

The junior research group is funded by ESF funds of the Free State of Saxony, in the period from July 2013 to December 2014 with a total of 977,000 EUR. Young scientists of the Faculty of Biosciences, Pharmacy and Psychology, Medical Faculty and the BBZ doctorate in various research projects for the development of novel drugs for the treatment of serious diseases.


last update: 20.12.2015 

Contact

Dr. Sylvia Els-Heindl
Universität Leipzig
Faculty for Biology, Pharmacy
and Psychology
Institute for Biochemistry
Brüderstr. 34
04103 Leipzig'
Phone: +49 341 97-36904
Fax: +49 341 97-36909
E-Mail

Prof. Dr. Annette Beck-Sickinger
Universität Leipzig
Faculty for Biology, Pharmacy
and Psychology
Institute for Biochemistry
Brüderstr. 34
04103 Leipzig

Phone: +49 341 97-36901
Fax: +49 341 97-36909
E-Mail

 
pages